Navigation Links
Schering-Plough Withdraws From Barclays Capital Global Healthcare Conference
Date:3/9/2009

KENILWORTH, N.J., March 9 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) will not present at the Barclays Capital Global Healthcare Conference in Miami, on Tuesday, March 10, as previously planned. We will be participating in various investor and employee communications related to the merger agreement with Merck announced earlier today, and therefore, will not be able to attend the conference.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
2. Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
3. Schering-Plough Selects Benefit Advocates for Health Advocacy
4. Schering-Plough Schedules Conference Call and Webcast for 2008 Fourth Quarter and Full Year Earnings
5. Schering-Plough Announces European Submission of Fertility Medicine Corifollitropin Alfa
6. Lupin Announces Litigation Settlement with Schering-Plough Corporation for Desloratadine(R)
7. Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
8. Schering-Plough to Webcast R&D Update Meeting
9. Physicians Rank Schering-Ploughs Marketing Messages for Asmanex as the Most Appealing in the Asthma Drug Market
10. Schering-Plough to Appeal Jury Decision in Missouri Reimbursement Case
11. Schering-Plough Reports Financial Results for Third Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and ... they are sponsoring a raffle. Throughout the month of February, patients who visit Hamlin ... gift card for a dinner for two at the Cheesecake Factory. , Tickets ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Dr. David Mahon ... Henderson, NV 89052. Dr. Mahon was named a 2017 Top Patient Rated Henderson ... is an online directory that recognizes local physicians and dentists who have earned high ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... community for those in the fight against cancer, has produced a seminal study ... HRA will release top-line findings in a webinar, Defining Compassionate Care Through ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist ... program today with a new Indiegogo campaign . Individuals are now able to ... the Los Angeles area, either as a participating patient or through an Indiegogo donation. ...
(Date:2/23/2017)... ... 23, 2017 , ... Carlos Gutierrez has lived his spiritual life ... evolve, which is the purpose of everyone in this universe. As Gutierrez sees the ... Balboa Press) attempts to guide readers to expand one’s spiritual life. , “Our Spiritual ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017 LG Innotek today announced that the company ... As its sterilization performance is 1.5 times higher than the competitor,s ... rays in the range of 200 -- 280nm, allowing it to be ... destroying their DNA. LG Innotek,s product emits UV in the range ... Until ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Cardiac Prosthetic Devices Market is ... next decade to reach approximately $8.9 billion by 2025. ... the given segments on global as well as regional levels presented ...
(Date:2/23/2017)... February 23, 2017 Tillotts Pharma ... Berlin office was opened in ... . The portfolio includes Entocort ® for the ... treatment of ulcerative colitis, and VistaPrep ® for ... Swiss specialty pharmaceutical company focused on the treatment of ...
Breaking Medicine Technology: